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Abstract
Background—We evaluated the effectiveness of a computer clinical decision support system 
(CDSS) for reducing the risk of QT interval prolongation in hospitalized patients.
Methods and Results—We evaluated 2400 patients admitted to cardiac care units at an urban 
academic medical center. A CDSS incorporating a validated risk score for QTc prolongation was 
developed and implemented using information extracted from patients’ electronic medical records. 
When a drug associated with torsades de pointes was prescribed to a patient at moderate or high 
risk for QTc interval prolongation, a computer alert appeared on the screen to the pharmacist 
entering the order, who could then consult the prescriber on alternative therapies and implement 
more intensive monitoring. QTc interval prolongation was defined as QTc interval >500 ms or 
increase in QTc of ≥60 ms from baseline; for patients who presented with QTc >500 ms, QTc 
prolongation was defined solely as increase in QTc ≥ 60 ms from baseline. End points were 
assessed before (n=1200) and after (n=1200) implementation of the CDSS. CDSS implementation 
was independently associated with a reduced risk of QTc prolongation (adjusted odds ratio, 0.65; 
95% confidence interval, 0.56–0.89; P<0.0001). Furthermore, CDSS implementation reduced the 
prescribing of noncardiac medications known to cause torsades de pointes, including 
fluoroquinolones and intravenous haloperidol (adjusted odds ratio, 0.79; 95% confidence interval, 
0.63–0.91; P=0.03).
Conclusions—A computer CDSS incorporating a validated risk score for QTc prolongation 
influences the prescribing of QT-prolonging drugs and reduces the risk of QTc interval 
prolongation in hospitalized patients with torsades de pointes risk factors.
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Torsades de pointes (TdP) is a potentially life-threatening polymorphic ventricular 
tachycardia associated with QT interval prolongation.1 More than 50 medications available 
in the United States may induce QT interval prolongation.2 TdP can be catastrophic in 
hospitalized patients, as it may degenerate into ventricular fibrillation and cause sudden 
cardiac arrest.3 The risk for TdP increases as the heart rate-corrected QT (QTc) interval 
increases,4,5 particularly when it exceeds 500 ms.6–8 Consequently, QTc interval 
prolongation is used widely as a marker of increased risk of TdP.
Hospitalized patients may be at greater risk of drug-induced QTc interval prolongation and 
TdP than outpatients because of a greater preponderance of risk factors, including structural 
heart disease, advanced age, electrolyte abnormalities, bradycardia, or kidney or liver 
disease.3 As many as 28% of patients admitted to cardiac care units present with QTc 
interval prolongation, and ≈1 of 5 have admitting QTc intervals >500 ms.9 Furthermore, 
more than one third of hospitalized patients with QTc interval prolongation on admission 
subsequently receive QT interval–prolonging drugs.9 QTc interval prolongation in critically 
ill patients is associated with increased duration of hospital stay, greater odds of in-hospital 
mortality,10 and increased risk of TdP.3
The American Heart Association and the American College of Cardiology Foundation 
published a scientific statement to raise awareness on the risk, ECG monitoring, and 
management of drug-induced QT interval prolongation and TdP in hospitalized patients.3 
The document emphasized risk factor knowledge and assessment and adequate monitoring 
of higher risk patients to minimize the likelihood of drug-induced TdP.3 However, reliable, 
effective strategies to mitigate the risk of drug-induced QT interval prolongation and TdP in 
high-risk hospitalized patients have not been developed.
Computerized clinical decision support systems (CDSSs) are information systems designed 
to improve clinical decision making.11 CDSS may improve prescribing of drugs, including 
warfarin, heparin, aminoglycosides, and others.11 Limited data suggest that implementation 
of specific CDSS may improve some patient outcomes.11 A primary limitation of many 
CDSS is alert desensitization, or alert fatigue, where clinicians frequently override alerts 
because of alert nonspecificity and the perception that the alert appears for all patients 
receiving specific drugs, rather than for patients truly at risk for the adverse drug reaction or 
drug interaction of interest.12,13 Incorporation of risk quantification into a CDSS, such that 
the appearance of the alert indicates that a patient is at increased risk of experiencing a 
specific adverse effect, may potentially minimize routine alert overrides and maximize 
CDSS use and effectiveness.
We tested the hypothesis that implementation of a computer CDSS incorporating a validated 
risk assessment for QTc interval prolongation reduces the prescribing of medications known 
to cause drug-induced TdP and decreases the associated risk of QTc interval prolongation in 
hospitalized patients with known TdP risk factors.
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Methods
Study Setting
This study was conducted in the cardiac care units (CCU) at Indiana University Health 
Methodist Hospital, a 747-bed university-affiliated tertiary care teaching institution located 
in Indianapolis. The CCU consists of one 28-bed cardiac critical care unit and one 28-bed 
cardiac progressive care unit, which primarily admit patients with cardiac diseases alone or 
with other medical problems. Typical diagnoses include acute myocardial infarction, heart 
failure, cardiac arrest, kidney disease, respiratory failure, and sepsis. A variety of physician 
staff attend these units, including cardiologists, heart failure specialists, critical care 
physicians and hospitalists. The study was approved by the Institutional Review Board at 
Indiana University Purdue University Indianapolis. The requirement for informed consent 
was waived.
Study Design
The design of this prospective, observational study is presented in Figure 1. The study 
consisted of 3 phases: (1) preintervention, during which the incidence of the primary and 
secondary end points were assessed before activation of the CDSS, (2) development of the 
CDSS, implementation into the institution’s computer system, functionality testing, 
modification and optimization of functionality, and healthcare provider education on CDSS 
function, and (3) activation of the computerized CDSS and subsequent assessment of 
primary and secondary study end points.
Phase 1: Preintervention Phase—Before implementation and activation of the 
computerized CDSS, data were collected from 1200 patients admitted to the CCU from 
October 2008 to October 2009. Exclusion criteria included <18 years of age, discharge from 
the unit in <24 hours, and those who were not undergoing daily ECGs or continuous cardiac 
rhythm monitoring. Patients with completely paced ventricular rhythms were excluded 
because of the difficulty in accurately measuring duration of ventricular repolarization with 
a paced QRS complex, and the lack of normative data on JT intervals as an alternative to the 
QT interval in paced rhythms. Patients were enrolled at the time of admission, and data were 
collected at admission and daily during hospitalization.
Data collected from computer and paper medical records included demographics, admitting 
diagnosis, current medical problems, past medical history, past and current medications, 
daily progress notes, and laboratory tests. All medications during hospitalization were 
recorded. Drugs were considered to be QT interval prolonging if evidence for causing QT 
interval prolongation and TdP was available from published trials or case reports.2 Table 1 
lists the drugs on the Indiana University Health Methodist Hospital formulary that were 
considered to be QT interval–prolonging drugs. Laboratory data were collected on 
admission and daily. Serum magnesium concentrations were available for some, but not all 
patients. Creatinine clearances were calculated from using the Cockcroft–Gault equation.14 
Serum potassium, magnesium, calcium, and creatinine concentration values are those at the 
time that QTc interval prolongation was initially documented. For patients who did not 
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develop QTc interval prolongation, these values are the lowest (potassium, magnesium, and 
calcium) or highest (creatinine clearance) reported during the patient’s hospitalization.
A baseline 12-lead ECG was obtained within 4 hours of admission in 867 (72.3%) patients. 
All patients underwent continuous cardiac telemetry monitoring. Daily QT intervals were 
measured by an investigator (H.J.; ≈90% of ECGs) or technician (≈10% of ECGs) from 
lead II of 12-lead ECGs or from continuous lead II telemetry strips using computer-
enhanced magnification and electronic calipers when possible (MUSE Cardiology 
Information System, GE Healthcare, Waukesha, WI). Inter-rater reliability was determined 
by comparing measurements on ≈5% of the ECGs (κ=0.90). QT intervals were measured 
from beginning of the earliest onset of the QRS complex to the end of the T wave, 
determined by extending a tangent from steepest portion of the downslope of the T wave 
until it crossed the T-P segment.15 During normal sinus rhythm, QT and R-R intervals were 
averaged from 3 consecutive complexes. During other rhythms, QT and R-R intervals were 
averaged over all complexes on the 6-second rhythm strips or 10-second lead II rhythm strip 
on the 12-lead ECGs. QT intervals were corrected for heart rate using Bazett’s formula 
(QTc).
QTc interval prolongation was defined as QTc interval ≥500 ms or an increase in QTc 
interval of ≥60 ms compared with the admitting value at any time during hospitalization; for 
patients who presented with QTc >500 ms, QTc interval prolongation was defined solely as 
increase in QTc of ≥60 ms from admitting value. As secondary analyses, the following 
alternate definitions of QTc prolongation were used16: (1) QTc interval ≥500 ms or an 
increase in QTc interval of ≥30 ms compared with the admitting value (for patients who 
presented with QTc >500 ms, the definition was increase in QTc interval of ≥30 ms from 
admitting value); (2) increase in QTc of ≥60 ms from admitting value; and (3) increase in 
QTc of ≥30 ms from admitting value.
Phase 2: Development of the CDSS, Functionality Testing, CDSS Modification, 
and Healthcare Provider Education—A computerized CDSS was developed that 
extracted information from electronic medical records of patients admitted to the CCU. The 
CDSS incorporated a validated risk score for QTc interval prolongation,17 and patient 
information extracted by the CDSS was based on known risk factors for QTc interval 
prolongation that are included in this risk score. Development and validation of the QTc 
prolongation risk score have been described previously.17 The QTc interval prolongation 
risk score is presented in Table 2. Serum magnesium concentrations are not included in the 
score because they were only obtained in 38% of patients admitted to the CCU. Patients 
were classified as being at low, moderate, or high risk of developing QTc interval 
prolongation during their hospitalization, based on risk scores of <7, 7 to 10, or ≥11, 
respectively.17
The computerized CDSS was incorporated into the institution’s computer platform (Cerner 
Corporation, North Kansas City, MO). Queries were designed and refined to extract 
information necessary to calculate the QTc interval prolongation risk score. When a patient 
was admitted to the CCU, the computerized CDSS immediately extracted patient 
information from the medical record to calculate the score. Age and sex were extracted from 
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demographics data. Serum potassium concentration closest to the time of order entry was 
used; point of care testing results were excluded. Other information extracted to calculate 
the risk score included diagnoses of acute myocardial infarction, determined by troponin 
>0.2 ng/mL (≈3× the upper limit of normal) or physician diagnosis; heart failure with 
reduced ejection fraction; sepsis; therapy with loop or thiazide diuretics; and QTc interval–
prolonging drugs. Medications were documented from the active medication list within 48 
hours of order entry. The QTc interval closest to the time of order entry from a 12-lead ECG 
loaded into the computer system was used to calculate the risk score. The computerized 
CDSS then calculated a QTc interval prolongation risk score for each patient admitted to the 
CCU. However, the CDSS was not displayed on the computer screen unless the following 
conditions were met: (1) an order was written for a QTc interval–prolonging drug; (2) the 
patient’s QTc interval prolongation risk score classified the patient as moderate risk (risk 
score, 7–10; corresponding to a 34%–50% risk) or high risk (risk score, ≥ 11; corresponding 
to a >50% risk) of developing QTc prolongation during the hospitalization; or (3) the 
patient’s admitting QTc interval was >500 ms. The list of QTc interval–prolonging drugs on 
the hospital’s formulary that was programmed into the computer to trigger the CDSS is 
presented in Table 1. The computerized CDSS was programmed into the institution’s 
computer system and was tested for functionality from October 2009 to March 2011, during 
which the computer alerts did not appear to clinicians, but ran in the background for CDSS 
testing and optimization.
Before activation of the computerized CDSS, pharmacy and physician staff were educated 
about the alert system. Pharmacy staff received 2 educational modules. The first was a web-
based program reviewing the clinical problem of QTc interval prolongation and TdP. The 
second was an in-person training session provided by pharmacists who acted as resources 
for the staff who reviewed functionality of the computerized CDSS and allowed the 
pharmacists time to practice with the CDSS. Physician staff underwent education during 
monthly meetings and received a brief email message describing the CDSS alert and the 
pharmacist’s role in the alert process. In addition, a cardiologist (R.K.) acted as resource and 
was available to physician staff to answer questions. Education was repeated as part of the 
orientation process for both pharmacists and physicians new to the hospital. The education 
process emphasized the fact that the appearance of the computer alert was based on 
validated risk assessment. Unlike many other computerized CDSS programs, particularly for 
drug interactions, these alerts did not appear for every patient for whom a QTc interval–
prolonging drug was prescribed, but only for those patients for whom there was a moderate 
(34%–50% risk) to high (>50%) risk of developing QTc interval prolongation based on the 
calculated QTc interval prolongation risk score.17 The computerized CDSS did not appear 
for patients for whom the calculated risk of developing QTc interval prolongation was low.
The computerized CDSS was activated in March 2011. The alert revealed the patient’s QTc 
prolongation risk score, categorized the patient’s risk as moderate or high, and indicated the 
specific risk factors that were contributing to the score. As computer physician order entry 
was not available at Indiana University Health Methodist Hospital at the time this study was 
conducted, the alert was directed to the pharmacists entering medication orders into the 
computer system. When an order for a QTc interval–prolonging medication was received by 
the hospital pharmacy, it was entered into the computer by a pharmacist. If the patient had a 
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calculated QTc interval prolongation risk score in the moderate or high range, the computer 
alert appeared on the screen to the pharmacist entering the order. When the alert appeared, 
the pharmacist had the following options: overriding the alert and taking no further action; 
contacting the prescribing physician, alerting him/her to the fact that the patient was at 
moderate or high risk, discussing risk mitigation strategies such as correction of serum 
electrolytes, where necessary, and performing more frequent measurement of QTc intervals; 
and where appropriate, discussing with the prescriber whether the QTc interval–prolonging 
drug could be discontinued and replaced with therapy with an alternate agent with less or no 
potential to cause QTc interval prolongation. The prescriber could also recommend that the 
alert be overridden, with no further action taken.
Intervention Testing: Effect of CDSS Implementation and Activation on Study 
End Points—Effectiveness of the CDSS was tested from March 2011 to October 2011. 
Data were collected prospectively from 1200 patients consecutively admitted to the CCU. 
The same exclusion criteria applied to the implementation group as to the 
preimplementation group. Data collected from computer and paper medical records were the 
same as those listed under preintervention phase. All patients underwent continuous cardiac 
telemetry monitoring and a baseline 12-lead ECG was obtained within 4 hours of admission. 
QTc intervals were measured and corrected as described in the pre-intervention phase.
Study End Points
Primary and secondary end points after implementation of the computerized CDSS were 
compared with those in the preintervention phase. Primary end points were (1) odds ratio 
(OR) for developing QTc interval prolongation, defined as a QTc interval >500 ms or an 
increase from admitting value of >60 ms at any time during the CCU hospitalization; for 
patients who presented with QTc >500 ms, the definition was increase in QTc interval from 
admitting value of ≥60 ms at any time during the CCU hospitalization; (2) OR for receiving 
therapy with a QTc interval–prolonging medication from any drug class; and (3) OR for 
receiving therapy with a noncardiac QTc interval–prolonging medication.
Secondary end points included (1) OR for developing QTc interval prolongation using 
alternate definitions of QTc interval prolongation: (a) QTc interval ≥ 500 ms or an increase 
in QTc interval of ≥30 ms compared with admitting value at any time during hospitalization 
(for patients who presented with QTc >500 ms, the definition was increase in QTc of ≥30 ms 
from admitting value), (b) increase in QTc interval of ≥60 ms from admitting value,16 and 
(c) increase in QTc interval of ≥30 ms from admitting value16; (2) proportion of patients 
who presented with pre-existing QTc interval prolongation (defined as admitting QTc 
interval ≥500 ms) who subsequently received therapy with a QTc interval–prolonging drug 
during the CCU hospitalization; (3) proportion of patients who had QTc interval 
prolongation directly associated with a QTc interval–prolonging medication; (4) proportion 
of patients with their highest documented QTc interval prolongation risk score of moderate 
versus high; (5) proportion of patients who experienced ≥1 episode of nonsustained 
monomorphic ventricular tachycardia (defined as ≥3 beats, but <30 seconds); and (6) 
proportion of computer CDSS alerts that were overridden.
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Statistical Analysis
Unpaired Student t tests were used to compare continuous variables, assuming equal or 
unequal variances between the groups, and χ2 or Fisher exact test, as appropriate, was used 
for categorical variables. Non-normally distributed continuous parameters were compared 
using the Wilcoxon rank-sum test. To calculate adjusted odds of QTc interval prolongation, 
independent predictors of QTc prolongation were determined. Univariate variables with P 
value ≤0.10 were incorporated into a bivariate logistic regression model in a forward 
stepwise fashion in descending order of those most strongly associated with QTc 
prolongation based on univariate P value. Significant continuous variables were 
dichotomized based on the results of the univariate analysis. Dichotomized variables were 
compared using the χ2 or Fisher exact test as appropriate. ORs with 95% confidence 
intervals (CIs) were determined for each variable. Analyses were performed using SPSS 
17.0 (SPSS, Inc, Chicago, IL).
Results
Patient Characteristics
Characteristics of patients in both study phases are presented in Table 3. The CDSS 
implementation group had a significantly lower proportion of women, white, and patients 
>67 years and a significantly higher proportion of patients with heart failure with reduced 
ejection fraction.
Primary End Points
Implementation of the CDSS resulted in a significant reduction in the adjusted OR of QTc 
interval prolongation in patients in the CCU (OR, 0.65; 95% CI, 0.56–0.89; Figure 2). 
Implementation of the CDSS did not result in a significant reduction in the adjusted OR of 
prescribing any QTc interval–prolonging drug (OR, 0.87; 95% CI, 0.77–1.12; Figure 2). 
However, implementation of the CDSS led to a significant reduction in the adjusted OR of 
prescribing noncardiac QTc interval–prolonging drugs (OR, 0.79; 95% CI, 0.63–0.91; 
Figure 2), primarily fluoroquinolone antibiotics and intravenous haloperidol.
Independent risk factors for developing QTc interval prolongation are presented in Figure 3. 
The odds of developing QTc prolongation were increased by known risk factors for QTc 
interval lengthening, including female sex, respiratory distress, diabetes mellitus, acute 
myocardial infarction, any arrhythmia, and receiving a loop diuretic or ≥1 QTc interval–
prolonging medication. Implementation of the CDSS was independently associated with a 
significant reduction in the odds of developing QTc interval prolongation.
Secondary End Points
Using the definition QTc interval ≥500 ms or increase in QTc interval of ≥30 ms compared 
with the admitting value during hospitalization (for patients who presented with QTc >500 
ms, defined as increase in QTc of ≥30 ms from admitting value), implementation of the 
CDSS significantly reduced the adjusted OR of QTc interval prolongation (OR, 0.78; 95% 
CI, 0.63–0.97). Using the definition increase in QTc interval of ≥60 ms from admitting 
value, implementation of the CDSS did not reduce the odds of QTc interval prolongation 
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(OR, 0.98; 95% CI, 0.87–1.39). Using the definition increase in QTc interval of ≥30 ms 
from admitting value, implementation of the CDSS did not reduce the odds of QTc interval 
prolongation (OR, 0.93; 95% CI, 0.79–1.33).
The proportion of patients who presented with pre-existing QTc interval prolongation who 
subsequently received a QTc interval–prolonging drug during the CCU hospitalization was 
reduced after implementation of the CDSS compared with the preintervention phase (57/163 
[35%] versus 64/97 [66%]; P<0.0001).
The proportion of patients who developed QTc interval prolongation directly associated with 
a medication was lower after implementation of the computerized CDSS than in the 
preintervention phase (116/1200 [9.7%] versus 203/1200 [16.9%]; P<0.001). The incidence 
of nonsustained monomorphic ventricular tachycardia was not significantly different in the 
preintervention phase than after implementation of the CDSS (3.8% versus 3.3%; P=0.29). 
No patients developed TdP in either study phase.
The proportion of patients with a high QTc interval prolongation risk score was lower after 
implementation of the CDSS compared with preintervention (4.4% versus 10.3%; 
P<0.0001). In contrast, the proportion of patients with a moderate QTc interval risk score 
was higher after implementation of the CDSS (41.1% versus 35.5%; P=0.003). There was 
no difference in the proportion of patients with a low QTc interval risk score after CDSS 
implementation compared with preintervention (54.5% versus 54.2%; P=0.87).
After CDSS implementation, there were 470 alert triggers. Of these, 382 (82%) were 
overridden: 59% of these were overridden by physician request, and 41% were overridden 
by pharmacists (Table 4). Of the 470 alert triggers, 51 (13%) resulted in additional 
monitoring including ECGs or more frequent laboratory monitoring or treatment of 
modifiable risk factors such as discontinuing other QT-prolonging medications and 
replacing electrolytes. The most common medication for which alerts were overridden was 
amiodarone (n=136).
The 470 alert triggers resulted in discontinuation of 84 (17.9%) medication orders. The most 
common drugs that were discontinued were intravenous haloperidol (n=23) and 
ciprofloxacin (n=18).
Discussion
A computer CDSS incorporating a validated QTc prolongation risk score reduced the odds 
of QTc interval prolongation and the prescribing of noncardiac QTc interval–prolonging 
drugs in patients in a CCU. Implementation of the computer CDSS also reduced the 
prescribing of QTc interval–prolonging drugs to patients admitted to the CCU with pre-
existing QTc interval prolongation.
QTc interval prolongation occurs commonly in patients in cardiac units.9 Furthermore, 
patients in cardiac units with pre-existing QTc interval prolongation are routinely prescribed 
QTc interval–prolonging drugs.9 Although risk factors for QTc prolongation and TdP are 
well documented,1,3 methods of identifying hospitalized patients at greatest susceptibility 
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for developing QTc interval prolongation have not been described previously. The odds for 
QT interval prolongation increase as the number of risk factors increases. Each 10-ms 
increase in QTc interval contributes to a ≈5% to 7% increase in risk for TdP.4 QT interval 
prolongation increases the odds of in-hospital mortality10 and is an independent risk factor 
for sudden cardiac death.18 The American Heart Association and the American College of 
Cardiology Foundation have sought to raise awareness among healthcare professionals 
about the risk of drug-induced QT interval prolongation and TdP in hospitalized patients,3 
particularly on risk factors and monitoring, to minimize the likelihood of drug-induced TdP. 
The American Heart Association/American College of Cardiology Foundation encourages 
QTc interval–monitoring strategies to identify patients who develop QTc interval 
prolongation.3 However, few strategies have been described to identify patients at greatest 
risk so that proactive steps may be taken to reduce the risk of progressing to QTc interval 
prolongation.
At the Mayo Clinic, Haugaa et al19 developed and implemented an institution-wide 
computer-based QT interval alert system, which screens all ECGs performed and alerts 
clinicians when the QTc interval is ≥500 ms. These investigators also developed a pro-QTc 
score, which assigned 1 point to diagnoses and conditions associated with QTc interval 
prolongation. The study found that all-cause mortality was higher in patients with QTc 
interval ≥500 ms compared with those with QTc interval <500 ms (19% versus 5%; P 
<0.001). The pro-QTc score predicted all-cause mortality. The authors reported that this QT 
interval alert system may increase clinicians’ awareness of prolonged QTc interval as a high-
risk indicator, and that reducing modifiable factors contributing to the pro-QTc score may 
facilitate life-saving interventions. Our work complements this work at the Mayo Clinic in 
several ways. First, we have developed and validated a QTc interval risk score that 
accurately predicts patients that are at moderate to high risk for developing QTc interval 
prolongation.17 Second, incorporation of that risk score into a computerized CDSS reduced 
the risk of QTc interval prolongation in patients in cardiac care units, in part, by encouraging 
amelioration of modifiable risk factors, as well as through influencing and reducing the 
prescribing of noncardiac QTc interval–prolonging medications. Therefore, although the 
Mayo Clinic alert notifies clinicians that a patient’s QTc interval exceeds 500 ms, our alert 
notifies clinicians when a patient is at moderate or high risk of developing QTc interval 
prolongation, so that steps can be taken to reduce the likelihood that QTc interval 
prolongation actually develops.
In the present study, we used as our primary end point a definition of QTc interval 
prolongation of >500 ms or an increase in QTc interval of ≥60 ms compared with the 
admitting value at any time during hospitalization (or for patients who presented with QTc 
>500 ms, an increase in QTc of ≥60 ms from admitting value). This end point was chosen 
based on data in patients with the long QT syndrome indicating that QTc interval >500 ms is 
associated with a 2- to 3-fold higher risk of TdP than QTc interval <500 ms20,21 and also 
based on data in patients with drug-induced TdP, which show a similar increased risk when 
the QTc interval is >500 ms.6–8 However, as there is no universally accepted consensus on 
the definitions of QTc interval prolongation, we also analyzed our data using other 
definitions.16 Using the definition QTc interval >500 ms or an increase of ≥30 ms compared 
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with admitting value (or for patients who presented with QTc >500 ms, an increase in QTc 
of ≥30 ms from admitting value), implementation of the CDSS significantly reduced the OR 
for QTc interval prolongation. A potential disadvantage of the above 2 definitions is that a 
patient could be admitted with a QTc interval between 490 and 500 ms, for example, and 
then during drug therapy experience a relatively small percentage increase from baseline to 
>500 ms and be counted in the QTc interval prolongation group. However, only 6% of 
patients in our study population presented with QTc interval 490 to 499 ms. We also 
analyzed the data using 2 definitions that did not include prolongation to >500 ms: an 
increase in QTc interval by ≥60 ms from admitting value and an increase in QTc interval by 
≥30 ms from admitting value. Using these definitions, CDSS implementation did not result 
in reduction in the odds of QTc interval prolongation. However, it should be pointed out that 
the QTc interval prolongation risk score that was incorporated into the CDSS and which 
identified patients as being at low, moderate, or high risk was developed and validated using 
the QTc interval prolongation definition used for our primary end point. Therefore, the 
validity of our QTc interval risk score using an alternate definition of QTc interval 
prolongation is unknown. Further, as described above, data indicate that QTc interval >500 
ms seems to be a critical threshold for an increased risk of TdP, rather than any specific 
increase in the interval from baseline. Using 2 definitions of QTc interval prolongation that 
included QTc interval >500 ms, our CDSS was effective for reducing the risk of QTc 
interval prolongation.
One of the primary limitations of many CDSS is alert fatigue, where clinicians frequently 
override alerts because of lack of specificity.12,13 Incorporation of risk assessment into a 
CDSS could minimize routine alert overrides and maximize CDSS use and effectiveness. In 
this study, our computer CDSS alert for QTc interval prolongation was specific and 
selective. Rather than appearing for every patient prescribed a QTc interval–prolonging 
drug, this alert was only displayed for patients prescribed a QTc interval–prolonging drug 
for whom there was a moderate to high risk of QTc interval prolongation based on 
assessment of QTc prolongation risk factors.17 Therefore, pharmacists who viewed an alert 
and physicians who were contacted about an alert knew that it was based on a validated 
quantification of risk. The CDSS alert override rate in this study was 82%, which is lower 
than override rates routinely reported in CDSS studies (often ≥90%).12,22,23 The lower alert 
override rate in this study may be a result of the more specific, selective nature of the CDSS 
alerts. Furthermore, overriding of an alert did not necessarily mean that no action was taken; 
in many cases, overriding of an alert meant that the QTc interval–prolonging medication that 
was ordered was not discontinued, but electrolyte supplementation was administered, 
another medication was discontinued, or more intensive QTc interval monitoring was 
performed.
In this study, implementation of the CDSS did not reduce the odds of prescribing of QTc 
interval–prolonging cardiovascular drugs, primarily amiodarone, but also including sotalol 
and other antiarrhythmic agents. Prolongation of ventricular repolarization is a major 
component of the efficacy of antiarrhythmic drugs. Furthermore, it is often difficult to 
replace a QTc interval–prolonging agent with a non–QTc interval-prolonging drug for 
arrhythmia management. Conversely, implementation of the CDSS significantly reduced the 
prescribing of noncardiac QTc-prolonging drugs, particularly fluoroquinolone antibiotics 
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and intravenous haloperidol. This suggests that implementation of the CDSS enhanced 
prescriber awareness of the problem of QTc interval prolongation, such that prescribers, 
where possible and appropriate, selected non–QTc interval-prolonging medications for the 
management of noncardiac conditions.
There were no occurrences of TdP in the CCU in this study. Even in the highest risk 
populations, TdP occurs rarely; Swedish investigators estimated an incidence of 4 cases of 
TdP per 1 000 000 persons annually.24 In our patients with cardiac disease and TdP risk 
factors, the incidence of TdP may be somewhat higher. Larger numbers of patients 
monitored for longer periods of time would be needed to demonstrate a survival benefit for a 
risk mitigation strategy. Although TdP occurs relatively rarely, it is a potentially avoidable 
catastrophic event in hospitalized patients, and consequently the American Heart 
Association/American College of Cardiology Foundation strongly recommends increased 
awareness of QT interval prolongation, TdP risk, QT interval monitoring, and avoidance of 
QT interval–prolonging medications where possible in hospitalized patients.3 Reducing the 
risk of drug-induced QTc interval prolongation with CDSS or other measures may reduce 
the risk of drug-induced TdP and possibly all-cause in-hospital mortality; this hypothesis 
requires testing in further studies.
Limitations of this work include the fact that the study was conducted in 2 cardiac care units 
in a single tertiary care institution, which may limit the generalizability of the results; the 
findings may not apply to patients in general medical wards. However, although the patient 
population was limited to cardiovascular/critical care, there were a variety of 
noncardiologist physician specialties represented among the physicians attending patients in 
these units. Although patients completely paced ventricular rhythms were excluded, patients 
with QRS duration >120 ms were included because clinicians working with this CDSS must 
make decisions about patients who may develop QTc interval prolongation, including those 
presenting with QRS >120 ms. Therefore, we included those patients to maximize external 
clinical applicability of the findings. The study used a pre- and postinterventional design, 
which can introduce temporal bias. The CDSS development phase included an educational 
component that was not included in the preintervention phase; the influence of the 
educational component on the intervention is unclear and requires assessment in future 
studies. These findings should be confirmed in a prospective, randomized, parallel group 
study, in which the educational component is accounted for; the current study provides 
support for such a trial.
In conclusion, a computer CDSS incorporating a validated risk score for QTc interval 
prolongation influences the prescribing of noncardiac QTc interval–prolonging drugs and 
reduces the risk of QTc interval prolongation in hospitalized patients with TdP risk factors. 
The results of this study provide support for a prospective, parallel group randomized study 
to evaluate the effectiveness of this or similar computer CDSS for reducing the risk of QTc 
interval prolongation and associated outcomes, including incidence of TdP and sudden 
cardiac death.
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WHAT IS KNOWN
• QT interval prolongation is a risk factor for torsades de points, a life-threatening 
arrhythmia.
• Reliable, effective strategies to mitigate the risk of drug-induced QT interval 
prolongation and torsades de pointes have not been developed.
WHAT THE STUDY ADDS
• A computer clinical decision support system was developed, incorporating a 
validated risk score for QT interval prolongation.
• This clinical decision support system alerted pharmacists entering orders for 
drugs that could provoke QT interval prolongation among specific patients at 
moderate or high risk of developing QT interval prolongation; the pharmacists 
then contacted prescribers to discuss risk mitigation strategies.
• Implementation of the computer clinical decision support system resulted in a 
significant reduction in the prescribing of noncardiac QT interval–prolonging 
medications and the risk of QT interval prolongation in patients hospitalized in 
cardiac care units.
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Figure 1. 
Study design. CDSS indicates clinical decision support system.
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Figure 2. 
Influence of a computerized clinical decision support system on the adjusted odds of 
developing QTc prolongation, the adjusted odds of prescribing of QTc interval–prolonging 
drugs from any drug class, and the adjusted odds of prescribing noncardiac QTc interval–
prolonging drugs.
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Figure 3. 
Independent risk factors for developing QTc prolongation during hospitalization in cardiac 
critical care units. MI indicates myocardial infarction.
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Table 1
QTc Interval–Prolonging Drugs on the Hospital Formulary That Were Programmed to Trigger the Appearance 
of the QTc Interval Prolongation Risk Alert if the Risk Score Classified the Patient as Moderate or High Risk
Drug Class Drug No. of Patients (Pre-CDSS) No. of Patients (After CDSS Activation) P Value
Antiarrhythmic Amiodarone 122 (10%) 142 (12%) 0.19
Disopyramide 2 (0.2%) 0 (0%) 0.50
Dofetilide 22 (2%) 4 (0.3%) <0.0001
Dronedarone 8 (1%) 11 (1%) 0.81
Ibutilide 2 (0.2%) 0 (0%) 0.50
Procainamide 2 (0.2%) 0 (0%) 0.50
Quinidine 1 (0.1%) 0 (0%) >0.99
Sotalol 36 (3%) 29 (2%) 0.45
Anti-infective Azithromycin 74 (6%) 65 (5%) 0.48
Clarithromycin 3 (0.3%) 0 (0%) 0.25
Ciprofloxacin 32 (3%) 24 (2%) 0.34
Erythromycin 3 (0.3%) 1 (0.1%) 0.62
Fluconazole 12 (1%) 8 (1%) 0.50
Levofloxacin 26 (3%) 16 (1%) 0.16
Moxifloxacin 18 (2%) 25 (2%) 0.36
Pentamidine 0 (0%) 0 (0%) >0.99
Voriconazole 1 (0.1%) 2 (0.2%) >0.99
Psychotropic Chlorpromazine 2 (0.2%) 0 (0%) 0.50
Droperidol 0 (0%) 0 (0%) >0.99
Haloperidol 46 (4%) 29 (2%) 0.06
Pimozide 0 (0%) 0 (0%) >0.99
Risperidone 5 (0.4%) 2 (0.2%) 0.45
Thioridazine 0 (0%) 0 (0%) >0.99
Ziprasidone 4 (0.3%) 3 (0.3%) >0.99
Other Methadone 6 (0.5%) 2 (0.2%) 0.29
Ranolazine 2 (0.2%) 3 (0.3%) >0.99
CDSS indicates clinical decision support system.
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Table 2
Calculation of Risk Score for QTc Interval Prolongation17
Risk Factor Points
Age ≥68 y 1
Female sex 1
Loop diuretic 1
Serum K+≤ 3.5 mEq/L 2
Admission QTc≥ 450 ms 2
Acute MI 2
1 QTc interval–prolonging drug 3
≥2 QTc interval–prolonging drugs 3
Sepsis 3
Heart failure 3
Maximum risk score 21
K+ indicates potassium; and MI, myocardial infarction.
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Table 3
Summary of Patient Characteristics
Characteristics* Preintervention Group (n=1200)
CDSS Implementation Group 
(n=1200) P Value
Age >67 y 576 (48%) 468 (39%) <0.0001
Women 606 (51%) 516 (43%) 0.0003
Race (white) 840 (70%) 792 (66%) 0.04
Admission diagnosis
 Acute AF 245 (20%) 264 (22%) 0.34
 Acute cardiac arrest 28 (2%) 38 (3%) 0.26
 Acute MI 139 (12%) 228 (19%) <0.0001
 Acute HF 435 (36%) 465 (39%) 0.21
 Unstable angina/PCI 304 (25%) 276 (23%) 0.18
 COPD exacerbation 111 (9%) 103 (9%) 0.61
 Acute infection (UTI, pneumonia) 120 (10%) 128 (11%) 0.58
 Sepsis 85 (7%) 82 (7%) 0.81
 Acute kidney injury 338 (28%) 302 (25%) 0.10
Comorbidities
 CAD 609 (51%) 601 (50%) 0.74
 HFrEF 325 (27%) 398 (33%) 0.0001
 Hypertension 849 (71%) 869 (72%) 0.37
 Diabetes mellitus 480 (40%) 528 (44%) 0.05
 COPD 201 (17%) 210 (18%) 0.63
 CKD 338 (28%) 305 (25%) 0.13
Medications
 β-blocker 709 (59%) 741 (62%) 0.18
 ACE inhibitor 512 (43%) 522 (44%) 0.68
 ARB 178 (15%) 189 (16%) 0.53
 Digoxin 164 (14%) 143 (12%) 0.20
 Loop diuretic 603 (50%) 625 (52%) 0.37
 1 QT interval–prolonging drug 372 (31%) 351 (29%) 0.35
 ≥2 QT interval–prolonging drugs 45 (4%) 52 (4%) 0.47
Laboratory values
 Serum K+ (mEq/L) 3.8±1.0 3.8±1.1 >0.99
 Serum K+ <3.5 mEq/L 492 (41%) 452 (38%) 0.09
 Serum Mg2+ <1.6 mg/dL 27 (6%; n=457) 60 (9%; n=677) 0.09
 Serum Ca2+, mg/dL 9.1±1.0 9.1±1.2 0.94
 Estimated creatinine clearance ≤50 mL/min 447 (37%) 430 (36%) 0.47
ECG
 Admission QTc, ms 451±41 450±55 0.87
 Maximum QTc, ms 471±37 474±43 0.14
 QT interval prolonged on admission 168 (14%) 179 (15%) 0.52
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Characteristics* Preintervention Group (n=1200)
CDSS Implementation Group 
(n=1200) P Value
 QT interval prolongation during hospitalization 340 (28%) 311 (26%) 0.18
 Heart rate, bpm 86±36 81±44 0.12
 Heart rate <60 bpm 126 (11%) 111 (9%) 0.30
ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; bpm, beats per minute; CAD, coronary 
artery disease; CDSS, clinical decision support system; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HF, heart 
failure; HFrEF, heart failure with reduced ejection fraction; K+, potassium; Mg2+, magnesium; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; and UTI, urinary tract infection.
*Continuous variables are expressed as mean±SD; dichotomous variables are expressed as number (%).
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Table 4
Reasons for Computer Alert Overrides (n=382)
Reason for Override n (%)
Physician-notified; ordered to continue medication 225 (59)
Patient’s condition warrants drug administration 58 (15)
Therapy appropriate as ordered 48 (9)
Laboratory test to be repeated, continue treatment 20 (5)
Not applicable to formulation 6 (2)
Patient on dialysis, continue treatment as ordered 2 (1)
Reference consulted, treatment appropriate 3 (1)
Treatment plan requirement 9 (2)
Other/unknown 11 (3)
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